Ral GPS1 Inhibitors

Brefeldin A and SecinH3 can alter vesicle trafficking and ARF-GEFs, respectively, which are processes that Ral GPS1 could be involved with, thereby affecting its function indirectly. Inhibitors such as NSC23766 and EHT 1864 that target the GTPase Rac1 and ML141 which targets Cdc42, can impact actin cytoskeleton organization, potentially affecting Ral GPS1's cellular role.

Additionally, chemicals that affect cell division and stress responses, such as Tozasertib and CCT007093, can have downstream effects on the cellular environment that Ral GPS1 operates within. MAPK/ERK pathway inhibitors like PD98059 and GW5074 can lead to changes in signal transduction pathways, potentially altering Ral GPS1 activity. Y-27632, a ROCK kinase inhibitor, can influence the actin cytoskeleton and associated signaling, thereby possibly impacting Ral GPS1's function. PI3K inhibitor LY294002 and phospholipase C inhibitor U73122 can disrupt various intracellular signaling pathways, potentially affecting Ral GPS1-associated processes. These compounds, through their targeted actions on specific signaling molecules and pathways, can indirectly influence the function and role of Ral GPS1 within the cell, making them part of the Ral GPS1 inhibitors class.